Our Principal, Pauli Wong, was invited to be one of the guest speakers at the “GBA Innovative MedTech Development Luncheon” on Wednesday (15 February) at HKSTP, sharing her insights on the unique IP challenges MedTech and healthcare innovations face in the GBA and China. The event was co-hosted by Society for Innovative Healthcare Hong Kong, Hong Kong College of Health Service Executives, GBA Medical Professional Study Tour, Doctors Think Tank Academy and CycloCorp.
Our Past Events
Recommended Insights
Compositions Limited by Use: A Cautionary Tale
26 October 2022Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
Read more >
Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]
20 February 2019Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]
Read more >
Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?
14 July 2020This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Read more >
Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical
12 December 2023Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
Read more >